

ASX Announcement

Imugene Presents Vaxinia Clinical Plan at the American Association for Cancer Research 2020 Annual Meeting

SYDNEY, Australia, 27 April 2020: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Seymour Fein will present the clinical plan for the initial trial of its oncolytic virus, Vaxinia (CF33-hNIS), at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting, scheduled for 27th-28th April 2020.

The abstract was originally accepted for the AACR Annual Meeting to be held in San Diego, 24th-29th April prior to the event being rescheduled as a virtual event due to the ongoing COVID-19 pandemic.

The abstract (number 9888) will be presented by Dr Seymour Fein, consulting Medical Director to Imugene Limited, virtually during the clinical session: VPO.CT07.01 Phase I Trials in Progress from 9.00am Eastern Daylight Time, USA, on Monday, April 27th.

The abstract presentation is entitled “A first-in-human phase 1 ascending, multiple dose, safety and tolerance study of Vaxinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adult patients with mixed advanced solid tumors (MAST)”, and was authored by Dr Seymour Fein and Imugene Limited.

The first-in-human, phase 1, multi-centre, dose escalation study of VAXinia (CF33-hNIS), is investigating intratumoural and intravenous administration lines as monotherapy and in combination with immune checkpoint inhibitors in a patient population with advanced or metastatic melanoma, non-small cell lung, TNBC, bladder, head and neck, gastric, colorectal and renal cell cancers.

The primary objectives of the phase 1 trial are to determine safety and a recommended phase 2 dose as monotherapy and in combination with immune checkpoint inhibitors. Efficacy and immune responses will also be measured.

The abstract title can be viewed on the AACR website at:

<https://www.abstractsonline.com/pp8/#!/9045/presentation/10671>.

The virtual presentation is also accessible via Imugene’s website and YouTube channel:

<https://youtu.be/KdXuV5lhwr0>

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

Follow us on Twitter [@TeamImugene](#)

Like us on Facebook [@Imugene](#)

Connect with us on LinkedIn [@Imugene Limited](#)

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.